Health
bioMérieux: BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Obtains De Novo FDA Authorization – Business Wire
Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary
MARCY LÉTOILE, France–(BUSINESS WIRE)–Regulatory News:
bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel. This panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause…
-
General21 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News18 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News17 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General14 hours agoQantas ‘contacted by potential cybercriminal’ after attack on data of up to 6 million customers